Association of RUNX3 Methylation with Clinical Outcome and Cell Migration/Invasion in Laryngeal Squamous Cell Carcinoma

Cancer Investigation

Volumn 34, Issue 2, 2016, Pages 105-113

  Liu, Zhao Hui ^a,b   Liu, Jia Jia ^a   Li, Shi Sheng ^a   Yang, Xin Ming ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b ZUNYI MEDICAL UNIVERSITY   (China)

Author keywords

Cell migration; DNA methylation; Expression; Laryngeal squamous cell carcinoma; Runt related transcription factor

Indexed keywords

AZACITIDINE; TRANSCRIPTION FACTOR RUNX3; DNA METHYLTRANSFERASE; ENZYME INHIBITOR; MESSENGER RNA; RUNX3 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CANCER STAGING; CANCER TISSUE; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA METHYLATION; DOWN REGULATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LARYNX SQUAMOUS CELL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SURVIVAL RATE; TUMOR GENE; AGED; ANTAGONISTS AND INHIBITORS; CELL MOTION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEAD AND NECK TUMOR; LARYNX TUMOR; METABOLISM; PATHOLOGY; SQUAMOUS CELL CARCINOMA; TIME FACTOR; TUMOR CELL LINE; TUMOR INVASION;

AGED; AZACITIDINE; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL MOVEMENT; CORE BINDING FACTOR ALPHA 3 SUBUNIT; DNA METHYLATION; DNA MODIFICATION METHYLASES; DOWN-REGULATION; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; TIME FACTORS;

EID: 84958546716     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2015.1104690     Document Type: Article

References (34)

1. M.S.Cattaruzza, P.Maisonneuve, P.Boyle. Epidemiology of laryngeal cancer. Eur J Cancer B Oral Oncol 1996;32B:293–305.
2. K.Chen, F.Song, M.He, H.Li, B.Qian, W.Zhang, et al. Trends in head and neck cancer incidence in Tianjin, China, between 1981 and 2002. Head Neck 2009;31:175–182.
3. K.Morshed, M.Polz-Dacewicz, M.Szymanski, D.Polz. Short-fragment PCR assay for highly sensitive broad-spectrum detection of human papillomaviruses in laryngeal squamous cell carcinoma and normal mucosa: clinico-pathological evaluation. Eur Arch Otorhinolaryngol 2008;265(Suppl 1):S89–S96.
4. Z.Li, W.Gao, W.Lei, W.Ho, Y.Chan, T.Wong, et al. The diagnostic value of methylated DNA in laryngeal squamous cell carcinoma: meta-analysis. Head Neck Oncol 2013;5:15.
5. S.Kada, S.Hirano, I.Tateya, M.Kitamura, S.Ishikawa, T.Kanda, et al. Ten years single institutional experience of treatment for advanced laryngeal cancer in Kyoto University. Acta Otolaryngol Suppl 2010;563:68–73.
6. A.Stembalska, P.Leszczyński, J.Gil, D.Ramsey, G.Pitala, A.Maciejczyk, et al. Global DNA methylation status in laryngeal cancer. Head Neck. 2014;36:419–424.
7. T.S.Wong, W.Gao, Z.H.Li, J.Y.Chan, W.K.Ho. Epigenetic dysregulation in laryngeal squamous cell carcinoma. J Oncol 2012;2012:739461.
8. J.Markowski, A.L.Sieron, K.Kasperczyk, M.Ciupinska-Kajor, A.Augusciak-Duma, W.Likus. Expression of the tumor suppressor gene hypermethylated in cancer 1 in laryngeal carcinoma. Oncol Lett 2015;9:2299–2302.
9. T.Furuta, T.Shuto, S.Shimasaki. DNA demethylation-dependent enhancement of toll-like receptor-2 gene expression in cystic fibrosis epithelial cells involves SP1-activated transcription. BMC Mol Biol 2008;9:39.
10. P.M.Severin, X.Zou, H.E.Gaub, K.Schulten. Cytosine methylation alters DNA mechanical properties. Nucleic Acids Res 2011;39:8740–8751.
11. S.B.Baylin, J.G.Herman. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000;16:168–174.
12. C.T.Wu, J.R.Morris. Genes, genetics and epigenetics: a correspondence. Sciences 2001;293:1103–1105.
13. Y.Ito. Oncogenic potential of the RUNX gene family: overview. Oncogene 2004;23:4198–4208.
14. Q.L.Li, K.Ito, C.Sakakura, H.Fukamachi, K.Noue, X.Z.Chi. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 2002;109:113–124.
15. M.Yanada, T.Yaoi, J.Shimada, C.Sakakura, M.Nishimura, K.Ito. Frequent hemizygous deletion at 1p36 and hypermethylation down-regulate RUNX3 expression in human lung cancer cell lines. Oncol Rep 2005;14:817–822.
16. C.Sakakura, K.Miyagawa, K.I.Fukuda, S.Nakashima, T.Yoshikawa, S.Kin. Frequent silencing of RUNX3 in esophageal squamous cell carcinomas is associated with radioresistance and poor prognosis. Oncogene 2007;26:5927–5938.
17. X.Y.Zhang, H.R.He, X.Zhang, W.J.Guo, Y.Q.Wang. RUNX3 promoter methylation is associated with hepatocellular carcinoma risk: a meta-analysis. Cancer Invest 2015;33:121–125.
18. S.H.Tan, H.Ida, Q.C.Lau, B.C.Goh, W.S.Chieng, M.Loh, et al. Detection of promoter hypermethylation in serum samples of cancer patients by methylation-specific polymerase chain reaction for tumour suppressor genes including RUNX3. Oncol Rep 2007;18:1225–1230.
19. M.Nishio, C.Sakakura, T.Nagata, S.Komiyama, A.Miyashita, T.Hamada. RUNX3 promoter methylation in colorectal cancer: its relationship with microsatellite instability and its suitability as a novel serum tumor marker. Anticancer Res 2010;30:2673–2682.
20. G.Marioni, R.Marchese-Ragona, G.Cartei, F.Marchese, A.Staffieri. Current opinion in diagnosis and treatment of laryngeal carcinoma. Cancer Treat Rev 2006;32:504–515.
21. S.B.Edge, C.C.Compton. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010;17:1471–1474.
22. D.Wang, W.Cui, X.Wu, Y.Qu, N.Wang, B.Shi, et al. RUNX3 site-specific hypermethylation predicts papillary thyroid cancer recurrence. Am J Cancer Res 2014;4:725–737.
23. Y.Xu, K.Wang, W.Gao, C.Zhang, F.Huang, S.Wen, et al. MicroRNA-106b regulates the tumor suppressor RUNX3 in laryngeal carcinoma cells. FEBS Lett 2013;587:3166–3174.
24. T.Y.Kim, H.J.Lee, K.S.Hwang, M.Lee, J.W.Kim, Y.J.Bang, et al. Methylation of RUNX3 in various types of human cancers and premalignant stages of gastric carcinoma. Lab Invest 2004;84:479–484
25. J.Tang, W.Bai, W.Ji, H.Gao, J.Liu. Relationship between hypermethylation of Runx3 gene and the development and metastasis of laryngeal carcinoma. J Clin Otorhinolaryngol Head and Neck Surg. 2010;24:834–837.
26. M.M.Subramaniam, J.Y.Chan, K.G.Yeoh, T.Quek, K.Ito, M.Salto-Tellez. Molecular pathology of RUNX3 in human carcinogenesis. Biochim Biophys Acta 2009;1796:315–331.
27. M.Pennison, B.Pasche. Targeting transforming growth factor-beta signaling. Curr Opin Oncol 2007;19:579–585
28. A.B.Roberts, M.A.Anzano, L.M.Wakefield, N.S.Roche, D.F.Stern, M.B.Sporn. Type beta transforming growth factor: a bifunctional regulator of cellular growth. Proc Natl Acad Sci USA 1985;82:119–123
29. E.C.Connolly, J.Freimuth, R.J.Akhurst. Complexities of TGF-beta targeted cancer therapy. Int J Biol Sci 2012;8:964–978
30. F.Chen, J.Bai, W.Li, P.Mei, H.Liu, L.Li, et al. RUNX3 suppresses migration, invasion and angiogenesis of human renal cell carcinoma. PLoS One 2013;8:e56241.
31. P.J.Mei, J.Bai, H.Liu, C.Li, Y.P.Wu, Z.Q.Yu, et al. RUNX3 expression is lost in glioma and its restoration causes drastic suppression of tumor invasion and migration. J Cancer Res Clin Oncol 2011;137:1823–1830
32. P.I.Hsu, H.L.Hsieh, J.Lee, L.F.Lin, H.C.Chen, P.J.Lu, et al. Loss of RUNX3 expression correlates with differentiation, nodal metastasis, and poor prognosis of gastric cancer. Ann Surg Oncol 2009;16:1686–1694
33. Q.Hu, L.Yu, R.Chen, Y.L.Wang, L.Ji, Y.Zhang, et al. 5-aza-2′-deoxycytidine improves the sensitivity of endometrial cancer cells to progesterone therapy. Int J Gynecol Cancer 2012;22:951–959.
34. J.Yang, X.B.Zhu, L.X.He, Z.W.Gu, M.Z.Jin, W.Y.Ji. Clinical significance of epigenetic silencing re-expression of O6-methylguanine DNA methyltransferase using epigenetic agents in laryngeal carcinoma. Oncol Lett 2015;9:35–42.